Welcome to our dedicated page for ASTRAZENECA PLC SEC filings (Ticker: AZN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on ASTRAZENECA PLC's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into ASTRAZENECA PLC's regulatory disclosures and financial reporting.
AstraZeneca reported positive interim Phase III results from the TULIP-SC trial showing subcutaneous Saphnelo (anifrolumab) met the pre-specified primary endpoint of reduced disease activity versus placebo in patients with moderately to severely active, autoantibody-positive systemic lupus erythematosus (SLE). The reduction in disease activity was measured by the BICLA at week 52, which requires improvement across organs without new flares. The interim analysis included the first 220 participants reaching week 52 from a randomised 1:1 trial of 367 participants receiving 120mg subcutaneous anifrolumab once weekly versus placebo on top of standard therapy. Safety was consistent with the known IV profile. Results are under regulatory review and slated for presentation at ACR Convergence 2025.
AstraZeneca reported top-line results from the RESOLUTE Phase III trial of Fasenra (benralizumab) in COPD. The trial randomized 689 participants with moderate to very severe COPD, all on background ICS/LABA/LAMA therapy and with elevated blood eosinophils (≥300 cells/µL). The primary endpoint—annualised rate of moderate or severe exacerbations in patients with ≥3 prior-year exacerbations—showed a numerical improvement with Fasenra but did not reach statistical significance. Safety and tolerability were consistent with Fasenra's known profile. AstraZeneca said it will analyse the full data set and share results with the scientific community. Fasenra is already approved for severe eosinophilic asthma and other eosinophilic conditions in multiple countries.
AstraZeneca reported its total voting rights and issued share capital. The company states that as at 31 August 2025 there are 1,550,692,963 ordinary shares of US$0.25 each carrying voting rights, with no shares held in treasury. This figure is presented so shareholders can use it as the denominator to determine whether they must notify changes in their holdings under the UK Disclosure and Transparency Rules.
The notice is a routine transparency disclosure and does not include financial results, transactions, or changes to capital structure beyond the voting‑rights count.
AstraZeneca issued a correction to a previously announced TR-1 notification. The Company states that a TR-1 submitted by The Capital Group Companies, Inc. and announced on 26 August 2025 was provided in error and should be disregarded. Shareholders are instead directed to the TR-1 notification relating to Capital Group that AstraZeneca announced on 21 August 2025, available via the referenced RNS link. The notice is administrative and clarifies which prior disclosure is the valid notification.
AstraZeneca PLC filed a foreign issuer report showing that an investor group linked to The Capital Group Companies, Inc. has crossed a key ownership threshold in the company.
According to the notification, Capital Group now holds 77,684,561 voting rights in AstraZeneca, equal to 5.009701% of the company’s voting rights, up from 4.997854%. This stake is held entirely through shares, with 62,998,778 voting rights in common stock (representing 4.062648%) and 14,685,783 voting rights via depository receipts (representing 0.947053%). No voting rights are held through derivative or other financial instruments, indicating a straightforward shareholding structure at this time.
AstraZeneca PLC furnished a Form 6-K reporting a notification of major holdings showing that The Capital Group Companies, Inc. and its affiliated investment managers crossed the 5% ownership threshold on 20-Aug-2025. The filing shows a resulting position of 77,500,852 shares, representing 5.009591% of voting rights, plus 14,685,540 depository receipts held indirectly (reported as 0.947037% indirect voting rights).
The disclosure explains the asset managers manage these shares on behalf of discretionary client accounts and that neither CGC nor its affiliates hold the shares for their own account. The Form 6-K is a routine, regulatory notification of significant institutional ownership rather than a corporate action by AstraZeneca.
AstraZeneca PLC reported a notification that its Executive Director and Chief Financial Officer, Aradhana Sarin, executed a sale of the company’s ordinary shares on 14 August 2025. The filing, provided on 18 August 2025, discloses a transaction price of £115.117 per share. The announcement follows EU Market Abuse Regulation reporting requirements as incorporated into UK law. The notice does not clearly state the number of shares sold in the visible text, so the total proceeds and percentage ownership change are not determinable from this filing alone.
AstraZeneca PLC received a TR-1 notification showing The Capital Group Companies, Inc. and its affiliates reported a combined holding of 77,682,857 ordinary shares, representing 4.984560% of voting rights as of 14-Aug-2025. Of that total, 14,351,342 are held as depository receipts (ISIN US0463531089), representing 0.925485% of voting rights. The filing clarifies these shares are owned by client accounts under discretionary management across Capital Group entities, not held for the parent companies' own accounts. The notification supplies the chain of controlled undertakings through which the holdings are managed and is signed by AstraZeneca's Company Secretary on 15 August 2025.
AstraZeneca received a TR-1 notification showing The Capital Group Companies, Inc. and its investment management affiliates crossed the 5% voting threshold in AstraZeneca ordinary shares on 11-Aug-2025. The notification reports a resulting total holding of 5.000629% of voting rights, represented by 77,294,699 underlying voting rights and 14,394,421 depository receipts (ISIN US0463531089) accounting for 0.928264% of voting rights. The filing discloses the full chain of controlled undertakings through which the holdings are held and explains these shares are owned by client accounts under discretionary management by Capital Group entities rather than for Capital Group's own account.